经导管主动脉瓣植入患者中的冠状动脉微血管功能障碍
本研究基于意大利维罗纳瓣膜性心脏病注册登记,回顾性分析250例接受TAVI的重度主动脉瓣狭窄患者,使用IMRangio定义CMD(≥30单位)。中位随访22个月,CMD患者主要终点(心血管死亡或心衰再住院)发生率显著更高(22.9% vs 2.8%),CMD为独立预测因素(校正HR 6.672)。
要点
- TAVI术前IMRangio≥30定义CMD,与不良预后独立相关。
- CMD患者主要终点发生率22.9%,无CMD者2.8%。
- CMD与晚期心外瓣膜损害(EVCD)相关。
核心结论
- CMD是TAVI术后心血管死亡和心衰再住院的独立预测因素。
研究设计与样本
- 回顾性分析意大利维罗纳瓣膜性心脏病注册登记,纳入250例重度AS接受TAVI患者(年龄83(80-86)岁,53%女性,2019-2021年)。
- 另在前瞻性31例TAVI患者中评估IMR与IMRangio相关性。
主要发现
- 中位随访22(IQR 12-30)个月,28例(11.2%)发生主要终点。
- CMD患者主要终点发生率22.9% vs 无CMD者2.8%(p<0.0001)。
- CMD患者晚期EVCD更常见(33例(31.4%) vs 27例(18.6%),p=0.024)。
- CMD独立预测不良结局(校正HR 6.672(2.251-19.778),p=0.001),并提供增量预后价值。
- IMRangio与有创IMR相关性尚可。
关键数值与推荐
- CMD定义为IMRangio ≥30单位。
- 晚期EVCD定义为肺循环受损、重度三尖瓣反流或右心室功能障碍。
- 主要终点为心血管死亡和心衰再住院的复合终点。
临床怎么用
- TAVI术前可通过冠状动脉造影计算IMRangio评估CMD,辅助风险分层。
- 合并CMD的TAVI患者术后需加强心衰和心血管事件监测。
局限性
- 回顾性分析,样本量250例,单中心注册登记。
- IMRangio与有创IMR的相关性仅在31例患者中前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aortic valve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD). Moreover, we sought to test the correlation between angiography-derived index of microcirculatory resistance (IMRangio) and invasive IMR in patients with aortic stenosis (AS). METHODS: This was a retrospective analysis of the Verona Valvular Heart Disease Registry (Italy) including 250 patients (83 (80-86) years, 53% female) with severe AS who underwent TAVI between 2019 and 2021. IMRangio was calculated offline using a computational flow model applied to coronary angiography obtained during the TAVI workup. CMD was defined as IMRangio ≥30 units.The primary endpoint was the composite of cardiovascular death and rehospitalisation for heart failure (HF). Advanced EVCD was defined as pulmonary circulation impairment, severe tricuspid regurgitation or right ventricular dysfunction.The correlation between IMR and IMRangio was prospectively assessed in 31 patients undergoing TAVI. RESULTS: The primary endpoint occurred in 28 (11.2%) patients at a median follow-up of 22 (IQR 12-30) months. Patients with CMD met the primary endpoint more frequently than those without CMD (22.9% vs 2.8%, p<0.0001). Patients with CMD were more frequently characterised by advanced EVCD (33 (31.4%) vs 27 (18.6%), p=0.024). CMD was an independent predictor of adverse outcomes (adjusted HR 6.672 (2.251 to 19.778), p=0.001) and provided incremental prognostic value compared with conventional clinical and imaging variables. IMRangio demonstrated fair correlation with IMR. CONCLUSIONS: CMD is an independent predictor of cardiovascular mortality and HF after TAVI.
引用
- Scarsini R, Portolan L, Della Mora F, et al. Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation. Heart. 2024. PMID: 38040448. doi:10.1136/heartjnl-2023-323461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。